GENE ONLINE|News &
Opinion
Blog

2022-04-14| China

Backed by RTW, LENZ Therapeutics Inks $110 Vision Loss Pact with China’s JIXING

by Joy Lin
Share To

LENZ Therapeutics, a San Diego-based clinical biopharma has announced a licensing deal worth $100 million with Shanghai-based Ji Xing Pharmaceuticals (JIXING) to develop two candidates for presbyopia. Additionally JIXING backer RTW Investments will invest $10 million in LENZ.    

Under the agreement, JIXING will pay $15 million upfront and up to $95 million in milestones in exchange for development and marketing rights to LENZ’s presbyopia treatments LNZ100 (aceclidine) and LNZ101 (aceclidine + beimonidine). LENZ will also get royalty payments based on future product sales. 

 

Eye Drops for Presbyopia  

 

Presbyopia is the gradual loss of the eye’s ability to focus on nearby objects. A natural part of the aging process, most notice it in their early to mid-forties. 

LENZ is developing eye drops to treat presbyopia. Their two candidates LNZ100 and LNZ101 contain aceclidine, a small molecule acetylcholine receptor agonist that makes the pupil contract. This creates a pinhole effect that improves near vision, without leading to a myopic shift and an increase in the degree of nearsightedness. 

Results from clinical trials on the eye drops suggest aceclidine can maintain pupil contraction for at least seven hours, and could correct distance vision. Aceclidine was well-tolerated; the most common side effect is mild discomfort when the eye drop is applied. 

LENZ is conducting INSIGHT, a clinical trial that will pave the way for a Phase 3 scheduled in the later half of 2022. 

“Age-related ophthalmic diseases are a growing challenge in China, with an estimated 440 million patients suffering from presbyopia,” said Joseph Romanelli, CEO of JIXING. “We have built a portfolio in presbyopia and dry eye disease and will continue to expand into more critical ophthalmic disease areas.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Roche Offers Up to $1 Billion for Avista to Develop Eye Disease Vectors
2022-07-20
Adverum Advances Wet AMD Gene Therapy After Cutting Jobs
2022-07-18
IPO
Belite Bio Clears Biopharma IPO Drought, with HilleVax and Tenon Medical Close Behind
2022-05-03
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!